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ttp://dx.doi.org/10.1016/j.ajpath.2014.02.027Hepatic production and release of endothelin-1 (ET-1) binding to endothelin B (ETB) receptors, overex-
pressed in the lung microvasculature, is associated with accumulation of pro-angiogenic monocytes and
vascular remodeling in experimental hepatopulmonary syndrome (HPS) after common bile duct ligation
(CBDL). We have recently found that lung vascular monocyte adhesion and angiogenesis in HPS involve
interaction of endothelial C-X3-C motif ligand 1 (CX3CL1) with monocyte CX3C chemokine receptor 1
(CX3CR1), although whether ET-1/ETB receptor activation inﬂuences these events is unknown. Our aim was
to deﬁne if ET-1/ETB receptor activation modulates CX3CL1/CX3CR1 signaling and lung angiogenesis in
experimental HPS. A selective ETB receptor antagonist, BQ788, was given for 2 weeks to 1-week CBDL rats.
ET-1 (BQ788) was given to cultured rat pulmonary microvascular endothelial cells overexpressing ETB
receptors. BQ788 treatment signiﬁcantly decreased lung angiogenesis, monocyte accumulation, and CX3CL1
levels after CBDL. ET-1 treatment signiﬁcantly induced CX3CL1 production in lung microvascular endothelial
cells, which was blocked by inhibitors of Ca2þ and mitogen-activated protein kinase (MEK)/ERK pathways.
ET-1einduced ERK activation was Ca2þ independent. ET-1 administration also increased endothelial
tube formation in vitro, which was inhibited by BQ788 or by blocking Ca2þ and MEK/ERK activation.
CX3CR1 neutralizing antibody partially inhibited ET-1 effects on tube formation. These ﬁndings
identify a novel mechanistic interaction between the ET-1/ETB receptor axis and CX3CL1/CX3CR1 in
mediating pulmonary angiogenesis and vascular monocyte accumulation in experimental HPS.
(Am J Pathol 2014, 184: 1706e1714; http://dx.doi.org/10.1016/j.ajpath.2014.02.027)Supported by NIH grant 5DKR01DK056804 (M.B.F.).
Disclosures: None declared.Cirrhosis and portal hypertension result in vascular alter-
ations in several organ systems, which impair the function
of these organs.1,2 The hepatopulmonary syndrome (HPS) is
one such complication, in which intrapulmonary vascular
abnormalities cause abnormal arterial gas exchange in 5% to
30% of cirrhotic patients.3e5 The presence of HPS signiﬁ-
cantly decreases quality of life and increases mortality in
those affected.6 Currently, the pathogenesis of vascular
alterations in HPS is incompletely understood, limiting the
development of effective medical therapies.
Chronic common bile duct ligation (CBDL) in the rat is an
established experimental model of HPS that reproduces the
physiological abnormalities of human disease.7e16 Thesestigative Pathology.
.animals develop pulmonary microvascular dilations and also
develop vascular remodeling, which is linked to the accumu-
lation of intravascular monocytes and vascular endothelial
growth factor-A (VEGF-A) production.11,12,17,18 Pulmonary
vasodilation results, in large part, from Ca2þ-dependent and
protein kinase B/Akteindependent activation of pulmonary
vascular endothelial nitric oxide synthase (eNOS)/NO, by he-
patic production and release of endothelin-1 (ET-1) and stim-
ulation of lung vascular endothelin B (ETB) receptors.
9,19 ET-1/
ETB receptor activation also enhances pulmonary vascular
ET-1 Modulation of Endothelial CX3CL1monocyte accumulation,14 thereby promoting angiogenesis
through monocyte VEGF-A production and activation of Akt
and ERK. However, how ET-1/ETB receptor activation mod-
ulates monocyte accumulation and whether ETB receptor acti-
vation has direct effects on angiogenesis are unknown.
We have recently found that the chemokine ligand/re-
ceptor pair C-X3-C motif ligand 1 (CX3CL1)/CX3C che-
mokine receptor 1 (CX3CR1) is up-regulated in the
pulmonary microvasculature after CBDL and contributes to
monocyte accumulation and to angiogenesis after CBDL.20
Interaction between the membrane-bound form of CX3CL1
with CX3CR1 is unique in the ability to cause ﬁrm adhesion
between cell types (monocyte-endothelium).21e24 In addi-
tion, the secreted soluble form of CX3CL1, through inter-
action with the CX3CR1 on endothelial cells, can drive
angiogenesis through Akt and ERK activation.25 However,
whether ET-1/ETB receptor activation after CBDL in-
ﬂuences monocyte accumulation or angiogenesis by
affecting lung CX3CL1/CX3CR1 expression has not been
tested. Therefore, the aims of the present study were to
deﬁne if the ET-1/ETB receptor activation modulates the
pulmonary CX3CL1/CX3CR1 axis and to determine how it
contributes to vascular remodeling in experimental HPS. To
do this, we assessed the effects of selective ET receptor
inhibition on pulmonary angiogenesis and CX3CL1/
CX3CR1 expression in vivo and evaluated the effects of
exogenous ET-1 on pulmonary microvascular endothelial
cell CX3CL1 expression and angiogenesis in vitro.
Materials and Methods
Animals
Male Sprague-Dawley rats (Charles River, Wilmington,
MA), 250 to 300 g, were subjected to CBDL (the common
bile duct was doubly ligated and divided) or sham operation
(mobilization of the common bile duct without ligation), after
i.p. injection of 80/10 mg/kg ketamine/xylazine to achieve
anesthesia.8,14,26 A selective ETB receptor antagonist, BQ788
(1  107 mol/day; Calbiochem, San Diego, CA), or saline
was given i.v. using a miniosmotic pump (ALZET model
2002; ALZET, Cupertino, CA) placed into the femoral vein
for 2 weeks to 1-week CBDL rats, as previously described.14
All assessments were made at 3 weeks after surgery. Eight
animals were used in each group. Portal venous pressure and
spleen weight were measured to evaluate the development of
portal hypertension. Lung and plasma samples were obtained
for further analysis. The study was approved by the Uni-
versity of Texas at Houston Health Science Center Animal
Welfare Committee and conformed to NIH guidelines on the
use of laboratory animals.
Arterial Blood Gas Analysis
Arterial blood was drawn from the femoral artery, as pre-
viously described,8,12,14 and analyzed on an ABL80 FLEXThe American Journal of Pathology - ajp.amjpathol.orgblood gas analyzer (Radiometer America, Westlake, OH).
The alveolar-arterial oxygen gradient (AaPO2) was calcu-
lated as follows:
150 ðPaCO2=0:8Þ  PaO2: ð1Þ
Immunoﬂuorescence and IHC Data
Sections (5 mm thick) of 4% paraformaldehyde, parafﬁn-
ﬁxed lung and liver tissues were blocked and incubated with
primary antibodies. For immunoﬂuorescent staining of ED1
(a monocyte marker; Serotec, Raleigh, NC) and factor VIII
(FVIII; Cell Marque, Austin, TX), Texas Red and ﬂuorescein
secondary antibodies (Vector Laboratories, Burlingame, CA)
and mounting medium with DAPI (Vector Laboratories)
were used. For immunostaining of ED1, ED2 (tissue resident
macrophage marker; Serotec), CD3 (T-cell marker; Abcam,
Cambridge, MA), and CD45R (B-cell marker; eBioscience,
San Diego, CA), biotinylated secondary antibodies were
used. After incubation with streptavidinebiotinehorseradish
peroxidase (Vector Laboratories), peroxidase activity was
detected with the DAB Peroxidase Substrate Kit (Vector
Laboratories). Sections are imaged with a Nikon Eclipse
E200 BinocularMicroscope (Nikon, Tokyo, Japan). Controls
are incubated with secondary antibody only.
Lung Microvessel Density Quantitation
The degree of pulmonary angiogenesis was evaluated by
quantifying microvessel densities in lung sections immuno-
stained with the endothelial marker FVIII, as previously
described.11,20 All stained objects were counted in a blinded
manner. Vessels with thick muscular walls or larger than 100
mm in diameter were excluded. Five randomly scanned ﬁelds
of three sections from each animal were investigated. The
average microvessel count in each group was expressed
relative to the count of the sham group as fold control values.
Endothelial Cell Culture
Rat pulmonary microvascular endothelial cells (RPMVECs;
Vec Technologies, Rensselaer, NY) were maintained and
subcultured in complete media MCDB-131 (Vec Technol-
ogies) at 37C in the presence of humidiﬁed 95% air and 5%
CO2. Cell passages were between 2 and 10.
Adenoviral RPMVEC Infection and Treatments
RPMVECs were plated in 6-well plates and allowed to reach
80% conﬂuence. Adenoviral-CMV-ETB receptor constructs
(1000 viral particle per cell) were added to cells for 24 to 48
hours to recapitulate in vivo alterations of HPS, as previously
described.19 Adenovirus-cytomegalovirusegreen ﬂuores-
cent protein (AdCMV-GFP) constructs were used as control.
After transfection, cells were stimulated with 1 to approxi-
mately 50 nmol/L ET-1 (Bachem Americas, Inc, Torrance,1707
Zhang et alCA) in the absence or presence of a selective ETB receptor
antagonist (BQ788) and speciﬁc inhibitors for the phospho-
lipase C (PLC)/InsP3/Ca
2þ/calmodulin pathway [U73122,
2-Aminoethoxydiphenyl borate (2-APB), BAPTA acetox-
ymethyl ester (BAPTA-AM), and W7], mitogen-activated
protein kinase (MEK)/ERK (U0126), and Akt (wortmannin)
(Calbiochem). Cell and supernatant CX3CL1 expression was
measured by real-time quantitative RT-PCR and enzyme-
linked immunosorbent assay (ELISA). Akt and ERK phos-
phorylation was assessed by using Western blot analysis.
Measurement of Cell Culture Medium CX3CL1 Levels
RPMVEC supernatant CX3CL1 levels were measured with
a commercial ELISA kit (Bio-Rad Laboratories, Hercules,
CA), according to the manufacturer’s instructions.
RNA Extraction and Quantitative Real-Time RT-PCR
Total RNA from lung or RPMVECs was extracted with
TRIzol (Invitrogen, Carlsbad, CA) reagent, according to the
manufacturer’s instructions, and treated with RNase-free
DNase I (Invitrogen), following the manufacturer’s proto-
col. cDNA was prepared using The High Capacity cDNA
Reverse Transcription kit (Life Technologies, Grand Island,
NY). Real-time PCR analysis was performed using the
StepOnePlus Real-Time PCR System and TaqMan Gene
Expression Master Mix (Life Technologies), according
to the manufacturer’s recommendations. TaqMan Gene
Expression Assays for rat CX3CL1 and CX3CR1 were from
Life Technologies. Expression levels were normalized to
expression of 18S rRNA.
Western Blot Analysis
Equal amounts of proteins from the lung or cell lysates,
obtained as previously described, were fractionated on
Criterion Tris-HCl Gel (4% to 20%; Bio-Rad Laboratories)
and transferred to a polyvinylidene diﬂuoride membrane
(EMD Millipore Corporation, Billerica, MA). Incubation
with primary antibodies against ED1, Akt, p-Akt (Ser473),
ERK, and p-ERK (Thr202/Tyr204; Cell Signaling Tech-
nology, Inc, Danvers, MA) was followed by addition of
horseradish peroxidaseeconjugated secondary antibodies
and detection with enhanced chemiluminescence substrate
Pico-West luminol reagent (Thermo Scientiﬁc Pierce,
Rockford, IL). The density of autoradiographic signals was
assessed with a ScanMaker i900 scanner (Microtek Lab,
Carson, CA) and quantitated with ImageJ software version
1.47 (NIH, Bethesda, MD).
Endothelial Tube Formation Assay
ET-1 stimulation of endothelial cell tube formation (in vitro
angiogenesis) was assessed by culturing RPMVECs on
growth factorereduced Matrigel (BD Biosciences, Franklin1708Lakes, NJ). RPMVECs were transfected with AdCMV-ETB
receptor constructs (1000 viral particle per cell) for 40 hours,
as previously described. A total of 4  104 transfected
RPMVECs per well were added to a 48-well plate coated
with Matrigel and incubated (Eagle’s basal medium-2 with
1.5% fetal bovine serum) for 3 to 12 hours at 37C. ET-1 (10
nmol/L) was administered in the presence or absence of
a selective ETB receptor antagonist (BQ788) and speciﬁc
inhibitors for the PLC/InsP3/Ca
2þ/calmodulin pathway
(U73122, 2-APB, BAPTA-AM, W7), MEK/ERK (U0126),
Akt (wortmannin), and an anti-CX3CR1 neutralizing anti-
body (Torrey Pines Biolabs, East Orange, NJ). Five random
ﬁelds per well were captured using a Nikon Eclipse E200
Binocular Microscope. Endothelial tubular structures were
skeletonized, and total tube length was quantiﬁed in a blinded
manner and expressed as fold control values.Statistics
Data were analyzed with the Student’s t-test or the analysis
of variance with Bonferroni correction for multiple com-
parisons between groups. Measurements are expressed as
means  SE. Statistical signiﬁcance was designated as
P < 0.05.Results
Selective ETB Receptor Inhibition Blocks Lung
Chemokine CX3CL1 Expression and Monocyte
Accumulation in Experimental HPS
To evaluate the speciﬁc effects of ETB receptor blockade on
lung monocyte alterations in experimental HPS, a selective
ETB receptor antagonist, BQ788, was given to 1-week
CBDL animals for 2 weeks, as previously described.14
Lung mRNA levels of CX3CL1 and its receptor,
CX3CR1, were measured by real-time RT-PCR. Monocyte
accumulation in the lung vasculature was assessed by ED1
(CD68, a pan-monocyte marker) immunohistochemistry
(IHC) and protein levels. Relative to sham animals, CBDL
animals developed signiﬁcant portal hypertension, reﬂected
by elevated portal venous pressure and spleen weight and a
widened AaPO2, indicating the development of HPS.
BQ788 administration to CBDL animals improved gas ex-
change abnormalities without inﬂuencing portal hyperten-
sion (Supplemental Figure S1), similar to prior reports.14
CBDL also resulted in a marked increase in pulmonary
CX3CL1 expression and endothelial staining, which was
accompanied by vascular monocyte inﬁltration, consistent
with our prior ﬁndings.20 These increases in lung were
signiﬁcantly attenuated by the blockade of the ETB receptor
with BQ788 (Figure 1). CX3CR1 mRNA levels also
increased in CBDL lung, reﬂecting the increase in monocyte
numbers on the basis of ED1 IHC and protein levels.
Accordingly, the decline in lung vascular monocyteajp.amjpathol.org - The American Journal of Pathology
Figure 1 Effects of ETB receptor inhibition
with BQ788 on lung CX3CL1/CX3CR1 levels and
monocyte accumulation after CBDL. A: mRNA
levels for CX3CL1 and CX3CR1 in lung. B: Repre-
sentative immunoﬂuorescence staining for ED1
(monocyte marker, red) in lung and representative
immunoblots and summary of lung ED1 protein
levels. Values are expressed as means  SEM
(nZ 8 animals for each group). *P < 0.05 versus
control; yP < 0.05 versus CBDL. Scale bar Z 50
mm. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase.
ET-1 Modulation of Endothelial CX3CL1accumulation after BQ788 administration was associated
with a reduction in lung CX3CR1 (Figure 1).
To deﬁne whether monocyte inﬁltration and modulation
by ETB receptor inhibition are selective events in the lung
after CBDL, we evaluated other immune cell types in the
lung and assessed liver monocyte subsets. At the light level,
cells inﬁltrating the lung appeared to be mononuclear and
stained for ED1, not ED2 (CD163, resident macrophage
marker) (Figure 1A and Supplemental Figure S2). When
CBDL lung (with and without BQ788 treatment) was
stained for CD3 (T-cell marker) and CD45R (B-cell
marker), there was no detectable accumulation, supporting a
selective inﬂux of monocytes (Supplemental Figure S3).
Both inﬁltrated circulating monocyte and resident macro-
phage (Kupffer cell) subsets contribute to liver injury after
CBDL.27e29 To determine whether systemic ETB receptor
blockade inﬂuences these cells, we assessed ED1 (monocyte
marker) and ED2 (resident Kupffer cell marker) staining.
There was a marked increase in both ED1 and ED2 staining
in the liver after CBDL, which was not inﬂuenced by
BQ788, supporting a lack of effect of ETB receptors on
monocyte alterations in the liver (Supplemental Figure S4).
Selective ETB Receptor Antagonist Decreases Lung
Angiogenesis and Angiogenic Signaling Pathway
Activation
To deﬁne whether changes in CX3CL1/CX3CR1 expression
and monocyte accumulation due to ETB receptor inhibitionThe American Journal of Pathology - ajp.amjpathol.orginﬂuence activation of angiogenic pathways and angiogenesis,
we assessed lung Akt and ERK activation and angiogenesis
after CBDL, with or without BQ788 treatment (Figure 2). Akt
and ERK phosphorylation and lung angiogenesis were signif-
icantly increased after CBDL, as previously described,11,20 and
were ameliorated by BQ788 administration.
Effects of ET-1 on CX3CL1 Expression in Pulmonary
Microvascular Endothelial Cells
To explore whether the ET-1/ETB receptor axis directly
inﬂuences endothelial CX3CL1 expression, we generated
ETB receptor overexpressing RPMVECs as an in vitro
model of pulmonary microvascular alterations in experi-
mental HPS (Supplemental Figure S5).14,17,19,30 CX3CL1
mRNA and supernatant protein levels were quantiﬁed by
real-time RT-PCR and ELISA. ET-1 administration to
control RPMVECs did not alter CX3CL1 mRNA or protein
production. ET-1 stimulation of ETB receptor over-
expressing RPMVECs induced a signiﬁcant dose- and time-
dependent increase in cellular CX3CL1 mRNA production
and supernatant protein levels (Figure 3A), which were
blocked by ETB receptor inhibition (Figure 3B).
To deﬁne pathways involved in ET-1 stimulation of
CX3CL1 in RPMVECs, we assessed activation of signaling
pathways recognized either to regulate endothelial CX3CL1
production or to be activated by ETB receptor stimulation,
PLC/InsP3/Ca
2þ/calmodulin, MEK/ERK, and Akt.19,31e33
ET-1 administration did not inﬂuence Akt activation in eitherFigure 2 Effects of ETB receptor inhibition with
BQ788 on pulmonary angiogenesis and Akt and ERK
phosphorylation after CBDL. A: Representative
immunoﬂuorescence images of lung microvessel
staining (FVIII, green) and quantitation of micro-
vessel density after CBDL. B: Representative im-
munoblots of p-Akt (Ser473) and p-ERK (Thr202/
Tyr204) after CBDL and summary of protein levels
for p-Akt/Akt and p-ERK/ERK. Values are expressed
as means  SEM (n Z 8 animals for each group).
*P < 0.05 versus control; yP < 0.05 versus CBDL.
Scale bar Z 50 mm. GAPDH, glyceraldehyde-
3-phosphate dehydrogenase.
1709
Figure 3 Effects of ET-1 on CX3CL1 production in ETB receptore
overexpressing RPMVECs. A: CX3CL1 mRNA and supernatant protein levels in
RPMVECs treated with 1, 10, and 50 nmol/L ET-1 for 4 and 8 hours,
respectively. B: CX3CL1 mRNA and supernatant protein levels in 10 nmol/L
ET-1etreated RPMVECs in the presence or absence of 10 mmol/L BQ788,
respectively, for 4, 8, and 16 hours. Values are expressed as means  SEM
(n Z 3 independent experiments in duplicate). *P < 0.05 versus control;
yP < 0.05 versus ET-1 treatment.
Figure 4 Effects of ET-1 on ERK activation in ETB receptore
overexpressing RPMVECs. Representative immunoblots and graphs summa-
rize ERK1/2 phosphorylation (Thr202/Tyr204) in RPMVECs treated with 1,
10, and 50 nmol/L ET-1 in the presence or absence of 10 mmol/L BQ788 for
5 minutes (A); and 10 nmol/L ET-1 in the presence or absence of 10 mmol/L
MEK/ERK inhibitor U0126 and inhibitors of PLC/InsP3/Ca
2þ/calmodulin
pathway (5 mmol/L U73122, 20 mmol/L 2-APB, 5 mmol/L BAPTA-AM, and 10
mmol/L W7, respectively) (B). Values are expressed as means  SEM (nZ 3
independent experiments in duplicate). *P < 0.05 versus control;
yP < 0.05 versus ET-1 treatment.
Zhang et alcontrol or ETB receptor overexpressing endothelial cells,
consistent with our prior in vitro ﬁndings (Supplemental
Figure S6).19 ET-1 stimulation of ETB receptor over-
expressing cells resulted in ETB receptoredependent ERK1/2
phosphorylation (Figure 4A and Supplemental Figure S3),
which was attenuated by speciﬁc MEK inhibition (Figure 4B),
but did not induce ERK activation in control cells
(Supplemental Figure S6A). The activation of ERK was not
altered by Ca2þ signaling pathway inhibitors, including
U73122 (PLC), 2-APB (InsP3), BAPTA-AM (calcium
chelator), and W7 (calmodulin), demonstrating Ca2þ-inde-
pendent MEK/ERK activation (Figure 4B). Inhibition of
either MEK/ERK activation or PLC/InsP3/Ca
2þ/calmodulin
signiﬁcantly attenuated ET-1einduced CX3CL1 mRNA and
protein production, whereas Akt inhibition did not (Figure 5).
Effects of ET-1 on VEGF-A Expression in Pulmonary
Microvascular Endothelial Cells
VEGF-A is also established to contribute to vascular
remodeling in experimental HPS.11,20 To evaluate if ET-1
modulates expression of VEGF-A in lung endothelium, we
measured VEGF-A mRNA levels after ET-1 administration1710in ETB-overexpressing pulmonary microvascular endothelial
cells. ET-1 stimulation did not inﬂuence VEGF-A expression
(Supplemental Figure S7).
Effects of ET-1 on In Vitro Angiogenesis in Pulmonary
Microvascular Endothelial Cells
To determine whether and how ET-1 modulates endothelial
cell angiogenic properties, we assessed tube formation after
ET-1 stimulation of ETB receptoreoverexpressing RPMVECs
in the presence or absence of BQ788 (Figure 6). Relative to
untreated cells, ET-1 stimulation resulted in a marked increase
in tube formation expressed by relative tube length. This in-
crease was completely inhibited by BQ788 pretreatment and
was signiﬁcantly inhibited by pretreatment with a neutralizing
CX3CR1 antibody. Accordingly, pretreatment of endothelial
cells with speciﬁc inhibitors of Ca2þ signaling andMEK/ERK
also signiﬁcantly decreased ET-1estimulated tube formation
to a similar degree to CX3CR1 inhibition.Discussion
Our prior work has demonstrated an important role for the
ET-1/ETB receptor system in the development of intra-
pulmonary vasodilation in experimental HPS, through theajp.amjpathol.org - The American Journal of Pathology
Figure 5 Effects of Ca2þ and MEK/ERK pathway inhibition on ET-1e
stimulated CX3CL1 production in ETB receptoreoverexpressing RPMVECs.
CX3CL1 mRNA and supernatant protein levels in RPMVECs treated with 10
nmol/L ET-1 in the presence or absence of inhibitors of MEK/ERK (10 mmol/
L U0126), PLC/InsP3/Ca
2þ/calmodulin pathway (5 mmol/L U73122, 20
mmol/L 2-APB, 5 mmol/L BAPTA-AM, and 10 mmol/L W7), and Akt (0.5
mmol/L wortmannin) for 4 (A) and 8 (B) hours. Values are expressed as
means  SEM (n Z 3 independent experiments in duplicate). *P < 0.05
versus control; yP < 0.05 versus ET-1 treatment.
ET-1 Modulation of Endothelial CX3CL1sequential activation of eNOS/NO signaling.14,15,19,30 We
have also shown that lung CX3CL1 expression is increased
after CBDL and drives the accumulation of VEGF-
Aeproducing monocytes and lung angiogenesis.20 In the
present study, we deﬁne that ET-1/ETB receptor activation
has a novel direct effect on lung microvascular endothelial
cell CX3CL1 expression, thereby linking these two path-
ways and the effects on the microvasculature. Speciﬁcally,
we found that ET-1 stimulation of ETB receptore
overexpressing RPMVECs in vitro directly increased
CX3CL1 expression through two independent intracellular
signaling pathways, MEK/ERK and Ca2þ. Furthermore,
inhibition of ET-1/ETB activation in vivo using a selective
ETB receptor antagonist signiﬁcantly reduced pulmonary
CX3CL1 expression, decreased vascular monocyte accu-
mulation, and improved angiogenesis and HPS. Finally, we
found that ET-1/ETB receptor activation in ETB receptore
overexpressing RPMVECs drives tube formation in vitro, in
part through increased CX3CL1 production. These obser-
vations directly link ET-1/ETB receptor activation and
endothelial CX3CL1 production in the pathogenesis of
pulmonary vascular alterations in experimental HPS.
In CBDL lung, monocyte accumulation and adhesion to
the microvasculature are important pathogenic features that
involve up-regulation and activation of the CX3CL1/
CX3CR1 pathway.12,20 A variety of stimuli are recognized
to increase CX3CL1 mRNA and protein expression in
vascular endothelial cells, including proinﬂammatory cyto-
kines (lipopolysaccharide, tumor necrosis factor-a, inter-
feron-g, and IL-1), glucose, and resistin.34e37 These stimuli
generally signal through several intracellular pathways,
including mitogen-activated protein kinases (ERK and p38),
NF-kB, and STAT-1, that modulate cellular CX3CL1
expression and shedding.38e40 Several of these pathways
are also activated by ET-1,31,33,41e44 which is up-regulated
after CBDL. In addition, ET-1 acting through either the ETA
or ETB receptor, has been established to increase production
of other chemokines and adhesion molecules in a variety of
cell types.45e47 Therefore, we hypothesized a potential link
between pulmonary microvascular ET-1/ETB receptor acti-
vation and CX3CL1 alterations in experimental HPS. Our
most important ﬁnding is that ET-1, via the ETB receptor,
directly induces ERK- and Ca2þ-dependent and Akt-
independent CX3CL1 production in rat pulmonary micro-
vascular endothelial cells. However, the signiﬁcance of this
ﬁnding is underlined by the in vivo observation that ETB
receptor blockade using BQ788 also reduces CX3CL1
levels in lung in conjunction with improving HPS after
CBDL. The ﬁnding that both mRNA levels and the secreted
form of CX3CL1 are increased in ET-1etreated endothelial
cells suggests that ET-1 may not only alter transcription,
but could also inﬂuence cleavage or shedding from the
membrane. CX3CL1 shedding occurs at the cell surface
within the transmembrane domain and is attributed to spe-
ciﬁc sheddases, a disintegrin and metalloproteases 10
and 17 (known as tumor necrosis factor-aeconvertingThe American Journal of Pathology - ajp.amjpathol.orgenzymes).48e50 Further studies are needed to deﬁne if and
how ET-1 directly inﬂuences shedding of CX3CL1.
Our prior work has shown that ET-1/ETB receptor acti-
vation of intracellular Ca2þ signaling stimulates eNOS
activation and NO-mediated pulmonary vasodilation, inde-
pendent of Akt activation after CBDL.19 This effect on Ca2þ
pathways is inﬂuenced by the level of ETB receptor
expression in the pulmonary microvasculature, which is
increased in the setting of elevated shear stress.19 Herein, we
conﬁrm that the level of ETB receptor expression in
RPMVECs inﬂuences cellular responses to ET-1 and that
ET-1 does not directly activate Akt in vitro. We do identify
ET-1 activation of both Ca2þ- and ERK-dependent path-
ways as important intracellular modulators of CX3CL1
expression. Lung Akt activation is increased in vivo during
angiogenesis after CBDL and is inhibited by ETB receptor,
CX3CR1, or VEGF-A blockade.11,20 These ﬁndings are
consistent with the concept that ET-1 effects on Akt in the
pulmonary endothelium in vivo are mediated indirectly,
through up-regulation of CX3CL1 autocrine/paracrine1711
Figure 7 Working model of the ET-1/ETB receptor axis and the pul-
monary vascular endothelial CX3CL1/CX3CR1 pathway in the development
of experimental HPS.
Figure 6 Effects of ET-1on endothelial tube formation in
ETB receptoreoverexpressing RPMVECs. Representative im-
ages of tubular structure formation and summary of relative
tube length in RPMVECs treated with 10 nmol/L ET-1 in the
presence or absence of inhibitors of 10mmol/L BQ788, 10ng/
mL antieCX3CR1-neutralizing antibody, 5 mmol/L MEK/ERK
inhibitor (U0126), and Ca2þ pathway inhibitors (2.5 mmol/L
U73122, 20 mmol/L 2-APB, and 5 mmol/L W7) for 6 hours.
Values are expressed as means  SEM (nZ 3 independent
experiments in duplicate). *P < 0.05 versus control;
yP< 0.05 versus ET-1 treatment. Scale barZ 200 mm.
Zhang et alsignaling and/or VEGF-A produced by adherent intravas-
cular monocytes; each of these events activates Akt and is
decreased by ETB receptor inhibition. These ﬁndings sup-
port that ET-1 initiates a cascade of alterations in the pul-
monary microvasculature in the setting of increased
pulmonary endothelial ETB receptor expression after
CBDL, which results in activation of multiple signaling
pathways in endothelial cells relevant to monocyte adher-
ence and angiogenesis.
The in vitro endothelial cell tube formation assays are
also consistent with direct and indirect effects of ET-1 on
angiogenesis in the pulmonary microvascular endothelium
in the setting of ETB receptor overexpression. The ﬁnding
that ETB receptor inhibition blocks ET-1 effects on
RPMVEC tubular structure formation is consistent with
prior ﬁndings that ET-1 directly induces endothelial cell
proliferation, migration, and angiogenic morphological
characteristics18,51,52 and with the in vivo studies in which
ETB receptor inhibition decreased angiogenesis. These ef-
fects are likely mediated through ERK and Ca2þ signaling
pathways.53,54 Our observation herein that blockade of
CX3CR1 also inhibits ET-1edriven tubular structure for-
mation supports that CX3CL1 production by ET-1 results in
autocrine effects on endothelial cell angiogenic potential.
These ﬁndings occur in parallel to the established in vivo
effects of CX3CL1 on monocyte adherence after CBDL.
These results support that ET-1 modulation of endothelial
CX3CL1 production is one key indirect pathway for inﬂu-
encing endothelial angiogenesis and monocyte adherence.
Future studies need to address the precise interaction
between ET-1 and CX3CL1 in pulmonary angiogenesis1712using genetic approaches to selectively ablate endothelial
CX3CL1 expression.
In endothelial cells from other tissues, ET-1 has been
reported to increase expression of members of the VEGF
family (VEGF-A and VEGF-C), indirectly regulating cell
proliferation and angiogenic responses.51,52,55 In contrast,
our in vitro studies herein demonstrate that ET-1 does not
increase VEGF-A expression in RPMVECs over a 4- to
18-hour time frame. This ﬁnding suggests that endothelial
production of VEGF in response to ET-1 may vary by tissue
and is consistent with the lack of effect of ET-1 on Akt
activation in RPMVECs. We have identiﬁed intravascular
monocytes recruited into the lung after CBDL as a major
source of VEGF-A production, supporting a paracrine
mechanism for monocytes in the development of lung
angiogenesis in experimental HPS.11,20 However, a degree
of VEGF-A staining has also been detected in the lung
microvasculature once experimental HPS has developed,ajp.amjpathol.org - The American Journal of Pathology
ET-1 Modulation of Endothelial CX3CL1suggesting that additional mediators and cell types may
modulate VEGF-A production in pulmonary microvascu-
lature in vivo after CBDL.
We have identiﬁed a novel synergistic interplay between
ET-1 acting through the ETB receptor and increased
CX3CL1 expression in RPMVECs that contributes to
altered angiogenic potential and inﬂuences monocyte
adhesion and the clinical expression of experimental HPS
(Figure 7). These effects occur through Ca2þ- and MEK/
ERK-mediated intracellular signaling pathways and are
supported by in vivo ﬁndings showing that ETB receptor
blockade inhibits lung angiogenesis and monocyte accu-
mulation by down-regulation of CX3CL1/CX3CR1
signaling. This direct link between hepatic ET-1 production
and pulmonary vascular alterations in experimental HPS
may have relevance to human disease on the basis of the
recent ﬁnding that hepatic venous ET-1 levels are elevated
in patients with pulmonary microvascular dilation relative to
those without pulmonary microvascular alterations.56 Un-
derstanding the cellular mechanisms of experimental HPS
may provide important insight into understanding and
treating human disease.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2014.02.027.
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